The thrombolytic activity of a novel modified t-PA,
YM866, was compared with that of a recombinant t-PA in a canine model of
copper coil-induced
coronary thrombosis. The coronary
thrombus was allowed to age for 1, 3 or 6 hr before either
drug was administered.
YM866 was administered by i.v. bolus injection, while t-PA was given by the same method, as well as by 60-min i.v. infusion.
YM866 showed thrombolytic activity 2 to 4 times as potent as that of t-PA when administered by bolus injection, the difference in thrombolytic effect being obvious in the 3- and 6-hr-old thrombi. Coronary reperfusion was achieved more rapidly with
YM866 than with i.v. infusion of t-PA. In animals injected with doses of more than 0.1 mg/kg of
YM866, no acute reocclusion occurred. Depletion of plasma
fibrinogen to 70% of baseline levels was observed in animals given 0.2 mg/kg
YM866, 0.4 mg/kg t-PA by bolus, and 0.6 mg/kg t-PA via infusion. The residual plasma
YM866 and t-PA
antigen 30 min after bolus injection was 25% and 3% of the peak levels, respectively.
YM866, administered by i.v. bolus injection, was thus confirmed to exert a thrombolytic effect superior to that of bolus injection and infusion of t-PA, without systemic fibrinolytic activation. These results suggest the potential clinical applicability of
YM866 as a
thrombolytic agent that can be administered by i.v. bolus injection for acute
myocardial infarction.